Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Andrew Tsai is an analyst at Morgan Stanley. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/19/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 03/19/2025 | BEKE | Buy Now | KE Holdings | $22.40 | 20.54% | Andrew Tsai32% | $19 → $27 | Maintains | Overweight | Get Alert |
| 12/18/2024 | RCKT | Buy Now | Rocket Pharmaceuticals | $8.46 | 242.79% | Andrew Tsai32% | → $29 | Initiates | → Buy | Get Alert |
| 10/25/2024 | MRNS | Buy Now | Marinus Pharma | — | — | Andrew Tsai32% | $5 → $0.5 | Downgrade | Buy → Hold | Get Alert |
| 10/21/2024 | SRPT | Buy Now | Sarepta Therapeutics | $79.90 | 106.51% | Andrew Tsai32% | → $165 | Initiates | → Buy | Get Alert |
| 09/17/2024 | RLMD | Buy Now | Relmada Therapeutics | $0.30 | 4247.83% | Andrew Tsai32% | $3.5 → $13 | Upgrade | Hold → Buy | Get Alert |
| 07/02/2024 | RAPP | Buy Now | Rapport Therapeutics | $9.44 | 270.76% | Andrew Tsai32% | → $35 | Initiates | → Buy | Get Alert |
| 03/19/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | — | — | Andrew Tsai32% | $10 → $21 | Downgrade | Buy → Hold | Get Alert |
| 02/27/2024 | ANRO | Buy Now | Alto Neuroscience | $3.01 | 996.35% | Andrew Tsai32% | → $33 | Initiates | → Buy | Get Alert |
| 12/07/2023 | VTGN | Buy Now | Vistagen Therapeutics | $2.67 | 461.71% | Andrew Tsai32% | $0.2 → $15 | Upgrade | Hold → Buy | Get Alert |
| 03/07/2023 | LXRX | Buy Now | Lexicon Pharmaceuticals | $0.35 | 768.06% | Andrew Tsai32% | → $3 | Initiates | → Hold | Get Alert |
| 06/23/2022 | ATHA | Buy Now | Athira Pharma | $0.35 | 757.14% | Andrew Tsai32% | $32 → $3 | Downgrade | Buy → Hold | Get Alert |
| 03/16/2022 | BEKE | Buy Now | KE Holdings | $22.40 | -28.57% | Andrew Tsai32% | $23 → $16 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 02/01/2022 | VIGL | Buy Now | Vigil Neuroscience | $1.93 | 936.27% | Andrew Tsai32% | → $20 | Initiates | → Buy | Get Alert |
| 09/20/2021 | ITCI | Buy Now | Intra-Cellular Therapies | $131.53 | -46.78% | Andrew Tsai32% | $55 → $70 | Maintains | Buy | Get Alert |
| 09/01/2021 | ATAI | Buy Now | ATAI Life Sciences | $1.41 | 1815.84% | Andrew Tsai32% | → $27 | Initiates | → Buy | Get Alert |
| 02/18/2021 | VTGN | Buy Now | VistaGen Therapeutics | $2.67 | 124.69% | Andrew Tsai32% | → $180 | Initiates | → Buy | Get Alert |
| 11/23/2020 | CERE | Buy Now | Cerevel Therapeutics Hldg | — | — | Andrew Tsai32% | → $18 | Initiates | → Buy | Get Alert |
| 10/13/2020 | ATHA | Buy Now | Athira Pharma | $0.35 | 8471.43% | Andrew Tsai32% | → $30 | Initiates | → Buy | Get Alert |
| 06/01/2020 | XENE | Buy Now | Xenon Pharmaceuticals | $34.94 | -34.17% | Andrew Tsai32% | $16 → $23 | Assumes | → Buy | Get Alert |
| 01/27/2020 | RLMD | Buy Now | Relmada Therapeutics | $0.30 | 24983.61% | Andrew Tsai32% | → $75 | Initiates | → Buy | Get Alert |
| 08/12/2019 | ITCI | Buy Now | Intra-Cellular Therapies | $131.53 | -87.84% | Andrew Tsai32% | → $16 | Initiates | → Buy | Get Alert |
